Home Health Dexcom’s Kevin Sayer talks new G7 scientific trial information

Dexcom’s Kevin Sayer talks new G7 scientific trial information

0

On the J.P. Morgan Healthcare Convention this week, Dexcom, maker of steady glucose monitoring programs, made waves after CEO Kevin Sayers introduced new scientific trial information from its but to be launched CGM, the G7. 

The 308 particular person trial demonstrated that the G7’s imply absolute relative distinction (MARD) was 8.2% for adults and eight.1% for pediatric sufferers. The G7 was submitted to the FDA within the fourth quarter of 2021 and remains to be awaiting regulatory clearance. 

On the monetary facet, Sayers revealed the corporate is predicted to make $2.448 billion in unaudited income for 2021, a 27% improve from 2020. On this upcoming yr, the corporate forecasts that it’s going to herald between $2.82 billion and $2.94 billion in complete income. 

MobiHealthNews sat down with Sayers to debate what’s subsequent for Dexcom and the way forward for diabetes care. 

MobiHealthNews: I would love to start out off with an outline of the information you introduced at J.P. Morgan and to listen to slightly bit extra in regards to the G7. 

Sayers: We closed the yr nicely. We grew 27% for the yr, and through a pandemic time in ’20 and ’21, we hung one other billion {dollars} of income on our outcomes. And I might problem anyone to do higher than what we have performed throughout these instances.

Massive information out of J.P. Morgan, and a few of the issues individuals are speaking to me about and asking us. We talked loads about our Dexcom One product that we launched in 4 European nations, and that is a chance. [It’s] the primary time we have differentiated on software program as a product, as a distinct product. We have by no means performed that earlier than. And doing that we predict is a giant a part of our future. We do assume that we are able to finally section this market into a few product strains after which be very profitable with it. …

The options of the G7 that I talked about probably the most … it is 60% smaller than our G6 and slightly bit larger than a nickel, slightly smaller than 1 / 4. It is actually very unnoticeable to individuals who put on it. It is a half hour heat up. … It’s nonetheless linked. It will likely be linked to everyone. However along with being interoperable and connectable, we have additionally enhanced cybersecurity right here. 

We actually have taken new expertise. Our circuit and chip within the G6 was developed means again within the 2016-17 timeframe, and cybersecurity and Bluetooth has superior considerably since then. So the brand new chips now we have on this will once more make folks really feel safer…

We have developed a brand new software program platform for this the place a few of your information that usually you’d discover in our CLARITY software – that are traits over an extended time frame – goes to be accessible proper within the app, and folks will due to this fact have the ability to look and see what their timing ranges for some time frame and get extra data. [It’s] simply a neater consumer expertise with respect to beginning up and every little thing we have realized. …

Then we get to the accuracy information. Dexcom has at all times been the perfect. …Finger sticks of their assessments again within the day had been like 10% off from laboratory blood instrument measurements. Our imply to common relative distinction is within the low eight with this product when in comparison with a laboratory instrumentation. So we’re getting near our finger sticks with the accuracy of this. Individuals can actually depend on it to make good selections and so they’ll really feel very snug with what they’ve. [It] once more units the bar greater for everyone else.

MobiHealthNews: I do know prior to now we have talked loads about possibly increasing past simply folks with diabetes. Is that also a consideration or is that also one thing that you are looking at sooner or later?

SayersThat could be very a lot one thing we’re sooner or later. And now we have relationships with a whole lot of early part firms which might be attempting in a licensed, accepted method. To be clear, they have the correct paperwork to get folks utilizing CGM for simply well being and wellness. And the outcomes from these guys have been actually good. 

Two research I talked about in my presentation, the Onduo research, which noticed reductions – and these had been the Kind 2 sufferers  however while you have a look at the mixed set of outcomes, [you see] higher cardiovascular outcomes, weight reduction, all types of issues. After which Welldoc ran a research once more in Kind 2 sufferers, however individuals who had a mean glucose above 180 on this cohort of sufferers. They used the product after 24 weeks of steady CGM, the place lowered common glucose by a mean of 54 factors. So you then get into different makes use of of the expertise, metabolic stuff. Any person involved about what they’re consuming or as prediabetes approaches. How shut are you? When do you begin a compound? Possibly to cease this factor?

MobiHealthNews: I would love to speak slightly bit extra in regards to the software program. How does Dexcom One change the sport for the longer term, and significantly Dexcom’s huge imaginative and prescient for the longer term? What sorts of capabilities are you able to foresee with including software program?

Sayers: With Dexcom One, what we did is we took options out. We made it a extra easy product that will justify a lower cost level. And we took a few of the alerts and alarm options out. We took the power to share information out. We took some issues out to make it a extra easy product and extra aggressive with what’s in these marketplaces. And so sooner or later, on the software program facet … I might see a day the place now we have a menu of options that both folks can get reimbursed for, or they will select to not use if they do not wish to, or they will pay for in the event that they’re extremely subtle. And what I would love is a platform whereby if folks develop these options, we are able to add tiles to our personal software program and make it so you will get out and use one other app and preserve Dexcom as your hub.

MobiHealthNews: What do you see as 2022 comes down the pipeline? What are a few of the greatest modifications in diabetes care that you are looking out for? And what are a few of the issues that you just foresee for Dexcom as nicely?

Sayers: One factor we might prefer to see is elevated entry all around the world to our expertise. And whereas it isn’t extremely technical, it is simply actually necessary. When this product is reimbursed and coated, folks come and get it and so they use it and so they have unimaginable experiences with it. …

I feel you may have some very thrilling developments on the pharmaceutical facet as folks preserve these new Kind 2 compounds. [They] look very thrilling and really partaking. It will likely be attention-grabbing to see how they roll out and the place that each one shakes out inside the drug firms. I do know they’re all working very exhausting on these compounds and so they seem to provide excellent outcomes.  

I feel the opposite factor in our world, we’re very a lot anticipating the launch of Omnipod 5 with insulin this yr. We have labored with insulin for a few years and we had been so excited to get this built-in product lastly.